PHARMACEUTICAL MANAGED ENTRY AGREEMENTS

Lessons Learned from Europe, the United States, Canada and Australia

Healthcare systems are struggling with balancing uncertainty and providing access to innovative health technologies.

A comprehensive literature review of the trends, challenges, and opportunities in key international markets was conducted by the authors to provide clarity on the feasibility of negotiating outcomes-based agreements.

Although payers’ and manufacturers’ objectives will never align completely, both parties ultimately have a common interest: to ensure that patients have timely and affordable access to innovative medicines. Managed entry agreements can play a crucial role in achieving that goal.

Please tell us where to send your Report?


We're committed to your privacy. MORSE may use the information you provide to us to contact you about our relevant content and services. Your name, address and all other personal information will not be sold or given to any other organization or list distributor. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

Pharmaceutical Managed Entry Agreements - Lessons Learned
css.php